Association between durable response (DR) and overall survival (OS) in patients with unresected stage IIIb-IV melanoma treated with Talimogene Laherparepvec (T-VEC) in the Phase III OPTiM trial

Gardado en:
Detalles Bibliográficos
Publicado en:J Immunother Cancer
Main Authors: Kaufman, Howard L, Andtbacka, Robert HI, Collichio, Frances A, Wolf, Michael, Li, Ai, Shilkrut, Mark, Puzanov, Igor, Ross, Merrick
Formato: Artigo
Idioma:Inglês
Publicado: BioMed Central 2014
Assuntos:
Poster Presentation
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4288773/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/2051-1426-2-S3-P91
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares